The Anti-Diabetes Drugs market in Hungary has shown significant growth in recent years, driven by various factors such as changing lifestyles, aging population, and increasing awareness about diabetes.
Customer preferences: Hungarian customers are increasingly opting for advanced anti-diabetes drugs that offer better efficacy, safety, and convenience. They prefer drugs that are easy to administer, have minimal side effects, and provide long-lasting effects. Additionally, there is a growing demand for personalized treatment options that cater to individual patient needs.
Trends in the market: The Hungarian Anti-Diabetes Drugs market has witnessed a shift towards newer drug classes such as GLP-1 agonists, DPP-4 inhibitors, and SGLT-2 inhibitors. These drugs offer several advantages over traditional therapies, including better glycemic control, weight loss, and cardiovascular benefits. Furthermore, there is a growing trend towards combination therapies that target multiple pathways to achieve better outcomes.
Local special circumstances: Hungary has one of the highest prevalence rates of diabetes in Europe, with around 7% of the population affected by the disease. This has led to a significant burden on the healthcare system, with diabetes-related complications accounting for a large proportion of healthcare spending. As a result, there is a growing emphasis on prevention and early intervention, with a focus on lifestyle modifications and regular screening.
Underlying macroeconomic factors: The Hungarian economy has been growing steadily in recent years, with a GDP growth rate of 4.9% in 2019. This has led to an increase in disposable income and a rise in healthcare spending. Additionally, the government has implemented several measures to improve access to healthcare services, including the introduction of a universal health insurance system and the expansion of primary care services. These factors are expected to drive the growth of the Anti-Diabetes Drugs market in Hungary in the coming years.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
